SFDA Implements New Good Clinical Practice Requirements for All Clinical Trials

Summary

The Saudi Food and Drug Authority has released updated GCP requirements aligned with ICH E6(R3). Major changes include enhanced risk-based monitoring, mandatory electronic informed consent capability, updated investigator site qualification requirements, and new data integrity provisions. All active trials must demonstrate compliance within 180 days of publication.